Last reviewed · How we verify
Xylometazoline - intranasal application
Xylometazoline is a selective alpha-1 adrenergic receptor agonist that constricts blood vessels in the nasal mucosa, reducing congestion and swelling.
Xylometazoline is a selective alpha-1 adrenergic receptor agonist that constricts blood vessels in the nasal mucosa, reducing congestion and swelling. Used for Nasal congestion due to rhinitis, sinusitis, or upper respiratory tract infections, Nasal congestion associated with allergic rhinitis.
At a glance
| Generic name | Xylometazoline - intranasal application |
|---|---|
| Sponsor | Association Asthma, Bulgaria |
| Drug class | Alpha-1 adrenergic agonist (nasal decongestant) |
| Target | Alpha-1 adrenergic receptor |
| Modality | Small molecule |
| Therapeutic area | Otolaryngology / Respiratory |
| Phase | FDA-approved |
Mechanism of action
By binding to alpha-1 adrenergic receptors on nasal blood vessels, xylometazoline causes vasoconstriction that decreases mucosal edema and nasal airway obstruction. This results in improved nasal airflow and relief of congestion symptoms. The intranasal application delivers the drug directly to the site of action with minimal systemic absorption.
Approved indications
- Nasal congestion due to rhinitis, sinusitis, or upper respiratory tract infections
- Nasal congestion associated with allergic rhinitis
Common side effects
- Nasal irritation or burning
- Sneezing
- Rebound congestion (with prolonged use)
- Headache
- Dizziness
Key clinical trials
- Hypertonic Saline Enhances The Field of View of Clinicians and Ease of Procedures (PHASE4)
- 4"S" - Seasonal Symptoms Suppression Study (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: